Galderma Stock Slides as Profit-Taking and FDA Concerns Outweigh Strong Earnings

Galderma (GALD) shares reversed early gains to trade lower on Tuesday, as a strong first-half earnings report and upgraded annual guidance were overshadowed by investor profit-taking and persistent regulatory concerns. The stock slipped 0.7% to 172.8 in the session after initially surging to an intraday high of 181, according to Investing.com.

Strong Results and Upgraded Outlook

The Swiss dermatology company reported robust financial performance for the first half of 2026, exceeding analyst expectations across key metrics. The results were driven by strong commercial momentum from its Nemluvio franchise.

Key highlights from the first-half report include:

• Net Sales: $3.13 billion, beating the consensus estimate of $3.06 billion.
• Constant-Currency Growth: 24.6%, ahead of the 22.3% anticipated by analysts.
• Core EBITDA: $802 million, surpassing the consensus forecast of $768 million.

Following the strong performance, Galderma raised its full-year 2026 net sales growth guidance to a range of 19% to 21%, up from its previous target of 17% to 20%.

Ad

Investor Concerns Temper Enthusiasm

Despite the positive financial results, the market's reaction was muted by several factors. The stock's pullback suggests investors chose to book profits following a significant run-up in the share price ahead of the earnings release.

A key overhang for the company remains the repeated U.S. Food and Drug Administration (FDA) pushback on its neuromodulator, Relfydess (RelabotulinumtoxinA). According to the source, this regulatory uncertainty places execution risk on Galderma's manufacturing and quality control processes.

Furthermore, analysts had previously noted that Galderma's already-elevated valuation was likely to limit the upside from a positive earnings surprise. The day's trading pattern appeared to confirm these valuation concerns, with the broader market's cautious tone providing little support.